Displaying 1 - 50 of 114 results
Released Company Title Industry Topic
21 Nov 2024
15:40 CET
LYTIX BIOPHARMA AS Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon completion 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
19 Nov 2024
07:00 CET
LYTIX BIOPHARMA AS Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization 20103010 Biotechnology Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
12 Nov 2024
10:10 CET
LYTIX BIOPHARMA AS Lytix Biopharma: Invitation to Q3 2024 Results Presentation 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
06 Nov 2024
13:34 CET
LYTIX BIOPHARMA AS First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma 20103010 Biotechnology Non-regulatory press releases
06 Nov 2024
13:34 CET
LYTIX BIOPHARMA AS Lovende fase II-studie i pasienter med tidligfase føflekkreft startet opp ved Radiumhospitalet - første pasient behandlet med Lytix’ kreftbehandling 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
05 Nov 2024
07:00 CET
LYTIX BIOPHARMA AS Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals 20103010 Biotechnology Non-regulatory press releases
05 Nov 2024
07:00 CET
LYTIX BIOPHARMA AS Lytix Biopharma – Oppdatering fra lisensieringspartner Verrica Pharmaceuticals 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
01 Nov 2024
07:04 CET
LYTIX BIOPHARMA AS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
01 Nov 2024
07:04 CET
LYTIX BIOPHARMA AS Finansiell kalender 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
24 Oct 2024
14:11 CEST
LYTIX BIOPHARMA AS Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
29 Aug 2024
08:00 CEST
LYTIX BIOPHARMA AS Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization 20103010 Biotechnology Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
23 Aug 2024
08:00 CEST
LYTIX BIOPHARMA AS Lytix Biopharma: Invitation to Q2 2024 Results Presentation 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
14 Aug 2024
13:37 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS: Phase II preliminary results from skin cancer (BCC) clinical trial show an 86 percent overall reduction of tumor size, complete clearance in half of the patients and the potential to be utilized as a first-line therapy 20103010 Biotechnology Innsideinformasjon
14 Aug 2024
13:37 CEST
LYTIX BIOPHARMA AS Lytix Biopharma: Foreløpige hovedresultater fra fase II-studie i pasienter med hudkrefttypen basalcellekarsinom viser 86 % total reduksjon i svulststørrelse, fullstendig fjerning av svulstene i halvparten av pasientene og potensial som førstelinjeterapi 20103010 Biotechnology Inside information
06 Aug 2024
16:38 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS: Lytix’ lisensieringspartner Verrica Pharmaceuticals publiserer foreløpige hovedresultater fra del 2 av deres fase II-studie av LTX-315 i hudkreftsykdommen basalcellekarsinom onsdag 14. august 2024 20103010 Biotechnology Non-regulatory press releases
06 Aug 2024
16:38 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from part 2 of their Phase II trial of LTX-315 for the treatment of the skin cancer disease basal cell carcinoma on August 14, 2024 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
30 May 2024
07:01 CEST
LYTIX BIOPHARMA AS Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones 20103010 Biotechnology Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
22 May 2024
11:47 CEST
LYTIX BIOPHARMA AS Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
14 May 2024
14:28 CEST
LYTIX BIOPHARMA AS Lytix Biopharma – Minutes of Ordinary General Meeting 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
13 May 2024
15:15 CEST
LYTIX BIOPHARMA AS LYTIX BIOPHARMA AS - NEW SHARE CAPITAL REGISTERED 20103010 Biotechnology Kapital- og stemmerettsendringer
03 May 2024
16:34 CEST
LYTIX BIOPHARMA AS Correction in the notice of Annual General Meeting in Lytix Biopharma AS 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
30 Apr 2024
07:05 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS: Notice of Annual General Meeting on 14 May 2024 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
30 Apr 2024
07:00 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS: Annual Report for 2023 20103010 Biotechnology Årsrapporter og revisjonsberetninger
26 Apr 2024
16:05 CEST
LYTIX BIOPHARMA AS LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDERS AND CLOSE ASSOCIATES 20103010 Biotechnology Meldepliktig handel for primærinnsidere
26 Apr 2024
15:48 CEST
LYTIX BIOPHARMA AS LYTIX BIOPHARMA AS – SHARE ISSUE PURSUANT TO BOARD AUTHORIZATION 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
25 Apr 2024
17:13 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates 20103010 Biotechnology Meldepliktig handel for primærinnsidere
25 Apr 2024
16:17 CEST
LYTIX BIOPHARMA AS LYTIX BIOPHARMA AS – MINUTES OF EXTRAORDINARY GENERAL MEETING AND FINAL RESULTS OF SHARE OFFERING 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
25 Apr 2024
13:46 CEST
LYTIX BIOPHARMA AS Lytix Biopharma annonserer godkjennelse av fase II-studie i pasienter med tidligfase føflekkreft (melanom) - en betydelig kommersiell mulighet 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
25 Apr 2024
13:46 CEST
LYTIX BIOPHARMA AS Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity. 20103010 Biotechnology Non-regulatory press releases
24 Apr 2024
21:54 CEST
LYTIX BIOPHARMA AS LYTIX BIOPHARMA AS – PRELIMINARY RESULTS IN THE SHARE OFFERING 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
24 Apr 2024
07:00 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS - Last day of the Application Period 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
12 Apr 2024
07:00 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS – Ex Date 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
10 Apr 2024
23:48 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS: Tilbud om tegning av aksjer, publisering av prospekt og innkalling til ekstraordinær generalforsamling 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
10 Apr 2024
14:20 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS – Notice of extraordinary general meeting 25 April 2024 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
10 Apr 2024
12:47 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS – Publication of Prospectus and commencement of Application Period 20103010 Biotechnology Prospekt / opptaksdokument
09 Apr 2024
18:12 CEST
LYTIX BIOPHARMA AS Lytix Biopharma AS - Key information relating to the share offer 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
09 Apr 2024
17:45 CEST
LYTIX BIOPHARMA AS Lytix Biopharma raising up to NOK 55 million with strong support from existing shareholders – several key milestones coming up with large commercial potential 20103010 Biotechnology Annen informasjonspliktig regulatorisk informasjon
09 Apr 2024
17:10 CEST
LYTIX BIOPHARMA AS LYTIX BIOPHARMA AS: Contemplated Offering 20103010 Biotechnology Innsideinformasjon
02 Apr 2024
12:54 CEST
LYTIX BIOPHARMA AS Lytix`s approach to raise response rates to immunotherapy highlighted in the international publication MedNous 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
21 Mar 2024
12:43 CET
LYTIX BIOPHARMA AS Lytix Biopharma announces the publication of a paper describing how LTX-315 mediates antitumor activity through multiple pathways 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
20 Mar 2024
14:54 CET
LYTIX BIOPHARMA AS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
29 Feb 2024
08:00 CET
LYTIX BIOPHARMA AS Lytix Biopharma Q4 and H2 2023 results: Promising interim results from multiple phase II studies, expanding clinical roadmap to early-stage cancer patients 20103010 Biotechnology Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
22 Feb 2024
10:36 CET
LYTIX BIOPHARMA AS Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2023 results, Thursday 29 February 2024 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
26 Jan 2024
12:42 CET
LYTIX BIOPHARMA AS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
23 Jan 2024
10:39 CET
LYTIX BIOPHARMA AS Lytix Biopharma presenting at Redeye Fight Cancer Event 2024 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
05 Jan 2024
15:18 CET
LYTIX BIOPHARMA AS Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
29 Dec 2023
17:58 CET
LYTIX BIOPHARMA AS Financial calendar 20103010 Biotechnology Additional regulated information required to be disclosed under the laws of a Member State
11 Dec 2023
13:14 CET
LYTIX BIOPHARMA Encouraging results from ATLAS-IT-04 study published in OncoImmunology 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger
09 Nov 2023
08:00 CET
LYTIX BIOPHARMA AS Lytix Biopharma presents third quarter 2023 results 20103010 Biotechnology Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
08 Nov 2023
12:00 CET
LYTIX BIOPHARMA AS Lytix Biopharma presenting at major investor conferences in London and Stockholm in November 20103010 Biotechnology Ikke-informasjonspliktige pressemeldinger